IMPORTANCE Stereotactic body radiotherapy is a hypofractionated, cost-effective treatment option for localized prostate cancer.
Introduction
Prostate cancer is the most common malignant neoplasm in men, with more than 164 000 new cases diagnosed in 2018. 1 With the advent and availability of prostate-specific antigen (PSA) testing enabling earlier detection of prostate cancer, most men are diagnosed as having localized disease.
Prostate cancer is stratified as low-, intermediate-, and high-risk disease based on tumor stage, PSA level at diagnosis, and Gleason score. 2 Treatment options for localized prostate cancer include active surveillance (reserved for low-risk individuals), radical prostatectomy with possible pelvic lymph node dissection, or radiation therapy (RT) entailing brachytherapy, external beam radiation therapy (EBRT), or both.
Fractionated EBRT typically involves a 9-to 10-week treatment with 1.8 to 2.0 Gy delivered daily. Technological advancements in parallel with improvements in treatment software enable more conformal EBRT planning, resulting in higher cumulative dose delivery while minimizing toxic effects. 3, 4 These innovations have promoted studies showing comparable toxicity profiles and noninferior outcomes between conventional EBRT given during 9 weeks to moderately hypofractionated regimens administered for 4 to 6 weeks. [5] [6] [7] Furthermore, the radiobiological rationale that a slow proliferation rate of prostate cancer is reflected by an α:β ratio of 2:3, similar to that of adjacent toxic effect-limiting organs, 8 suggests that extremely hypofractionated radiation regimens will provide comparable cancer control rates without increasing toxic effects.
Stereotactic body radiotherapy (SBRT) is an extremely hypofractionated regimen of 7 to 10 Gy per fraction delivered using stereotactic or image-guided intensity-modulated RT techniques.
Stereotactic body radiotherapy is most commonly completed in 5 total fractions, enabling patients to finish their treatment in fewer visits, thereby increasing convenience while lowering health care costs. Numerous studies have validated 5-fraction prostate SBRT as a cost-effective, noninvasive treatment achieving outcomes equivalent to conventionally fractionated EBRT or to surgery without compromising safety. [9] [10] [11] [12] [13] These findings have culminated in National Comprehensive Cancer Network guidelines supporting 5-fraction prostate SBRT use at facilities with appropriate technology and physics and clinical expertise. 2 The present study aims to characterize national trends in SBRT use.
Methods

Data Source
The National Cancer Database (NCDB) is an oncology-focused national database established by the American College of Surgeons and the Commission on Cancer of the American College of Surgeons.
The NCDB tabulates longitudinal data from more than 70% of all new cancer diagnoses on an annual basis, encompassing more than 1500 hospital across all 50 US states. 14 The collected data include cancer characteristics, primary and adjuvant management, and long-term outcomes, as well as patient demographic information, such as age, sex, race/ethnicity, educational level, income, and insurance status. 15 The present study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies. Because the study used deidentified data from the NCDB database, the requirement for formal institutional review and the 
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Study Population
The NCDB was queried to identify patients diagnosed as having localized prostate cancer from 2010 to 2015 who underwent definitive RT. Stereotactic body radiotherapy was defined as patients undergoing treatment with 5 fractions of EBRT. Prostate cancer diagnoses were made via biopsy of the primary site. Patients were excluded from analysis if they lacked sufficient clinical data to assess their disease risk stratification, received a diagnosed at the reporting facility but had their treatment decision made elsewhere, or underwent surgery or chemotherapy as part of their initial treatment.
They were also excluded if their RT total dose appeared erroneous (eg, SBRT<30 Gy or >50 Gy).
Patients meeting all of the following criteria were classified as having low-risk disease: American Joint Committee on Cancer (AJCC) tumor category cT1a to cT2a, Gleason score of 6 (with lower numbers indicating cells that are well differentiated and look similar to healthy cells), and PSA level less than 10 ng/mL (to convert PSA level to micrograms per liter, multiply by 1 
Statistical Analysis
Descriptive statistics for factors of interest were reported as frequency (percentage). The Cochran-Armitage test was used to identify significant trends in the use of SBRT with time and by risk category. Multivariable logistic regression was performed to examine clinical and sociodemographic factors associated with SBRT use. All tests were 2-sided and considered significant at an α level of .05.
All analyses were performed using SAS software, version 9.4 (SAS Institute Inc). Initial analyses were performed between January and February 2018, with final updates performed August 2019.
Results
Demographic and clinical characteristics are given in Abbreviations: AJCC, American Joint Committee on Cancer; PSA, prostate-specific antigen.
SI conversion factor: To convert PSA levels to micrograms per liter, multiply by 1. 
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Discussion
Using a population-based cohort of patients with newly diagnosed prostate cancer, we provide a descriptive analysis of the largest study to date, to our knowledge, exploring trends in the use of SBRT as a definitive treatment modality. Our analyses included 106 926 patients receiving EBRT, of whom 5395 underwent SBRT. The most frequently used total dose for a SBRT treatment course was 36.25 Gy delivered in 5 fractions, which is consistent with prior studies evaluating extreme hypofractionation regimens. [9] [10] [11] [12] The use of SBRT has more than doubled from 3.1% in 2010 to 7.2% in 2015. These observations are in line with prior studies showing an increase in SBRT use from less than 0.4% in 2004 to 4.0% in 2012. 16, 17 Although this trend persevered among all risk groups, men who underwent SBRT were more likely than those undergoing EBRT to have low-risk disease or favorable intermediate-risk disease, which is consistent with earlier studies. 16, 18, 19 Conversely, the number of patients receiving EBRT steadily decreased from 2010 to 2015, which is largely reflective context of emerging long-term treatment outcomes showing favorable comparisons with other radiation modalities. 13 Nevertheless, larger cohorts and long-term data are required to adequately assess the efficacy of SBRT in higher-risk disease.
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As mentioned previously, the proportionally smaller but substantial number of unfavorable intermediate-risk and high-risk patients receiving SBRT and ADT may be attributed to enrollment in clinical trials or to mitigation of burdens due to medical comorbidities or socioeconomic stressors among selected patients. Among the high-risk cohort, 76.6% received ADT, coinciding with a prior study by Chen et al 21 reporting that 1 of 4 high-risk patients are not treated with ADT. In their analysis,
ADT was often omitted in men treated with EBRT and a brachytherapy boost, which was not captured in our data. Androgen deprivation therapy may also be omitted because of patient or physician preference related to its adverse effect profile, which includes sexual dysfunction, osteopenia, metabolic changes, and cardiac toxic effects as well as emerging evidence suggesting that ADT may be associated with depression, cognitive dysfunction, 22 and the development of Alzheimer disease. 23 In addition, a study by D'Amico et al 23 reporting that the benefit of ADT for intermediate-risk and high-risk patients with 7.6 years of follow-up no longer showed a significant benefit after 16 years may give pause to clinicians prescribing ADT because its prostate cancerspecific benefits must be weighed against its adverse effects. of the low-risk disease population was prescribed ADT between 2004 and 2012. 24 Yang and colleagues 25 attributed ADT use among patients with low-risk disease undergoing EBRT to treatment in nonacademic centers and to the influence of regional practice patterns. In addition, patients with low-risk disease and with favorable intermediate-risk disease may receive ADT to decrease gland size to allow for SBRT. Although the proportion of patients with lower-risk disease treated with ADT is decreasing, 24 these findings warrant efforts to ensure dissemination of recent data on ADT in the community setting.
Patients undergoing radiotherapy at academic centers were more likely than those treated outside such centers to receive SBRT. This finding is concordant with a prior study by Weiner et al 17 that showed from 2004 to 2012, SBRT use increased by 7.0% in academic centers, but only by 1.3% in nonacademic institutions. Academic institutions are more likely to obtain and use new treatment modalities and are able to safely evaluate novel management strategies in a clinical trial setting. In addition, they are more likely to be equipped with the necessary technology as well as the physics and physician expertise required for implementation. Prior studies report that a majority of prostate SBRT occurred in the Northeast, which was attributed to a preponderance of academic institutions and facilities with appropriate staffing and technology concentrated in these areas. 16, 26 Conversely, our analysis found that patients in New England and on the Pacific Coast had lower odds than other regions in the United States of receiving SBRT.
Differences in selection of SBRT may reflect patient and physician preference for other treatment regimens or modalities with more robust long-term disease-specific control and safety data compared with that of the existing SBRT literature. [9] [10] [11] [12] [13] Some physicians cite existing data on moderate hypofractionation showing equivalent disease control but with higher grade 2 or worse toxic effects 6 as a reason to wait on more extensive follow-up before routinely using extreme hypofractionation in their practice. In addition, physician and physicist exposure to hypofractionated and stereotactic treatments in training as well as investing in additional technologies to facilitate effective SBRT delivery, such as fiducial markers, rectal balloons, and implantation of spacers to help protect organs at risk (eg, SpaceOAR Hydrogel), may influence physician selection of SBRT. Healthier patients were more likely to receive SBRT. Given the slowly progressive nature of prostate cancer, patients with preexisting medical conditions will more likely succumb to those competing comorbidities. Thus, patients with estimated life expectancies of less than 10 years are preferably observed than recommended definitive treatment of their prostatic malignant neoplasm. 2
Among patients with robust estimated life expectancies, the ensuing prostate cancer management entails interdisciplinary discussions in conjunction with each patient's preference, intricacies that cannot be fully captured by a database. For example, EBRT may be preferably offered to men who are not deemed surgical candidates owing to their existing comorbidities. By contrast, patients may elect prostatectomy because of preference or to avoid the adverse effects of concurrent ADT with EBRT.
Our analyzed population comprised significantly more white men than black men, the former of which had higher odds of receiving SBRT than other races/ethnicities. Men with higher incomes were more likely to receive SBRT, which was previously discussed in earlier studies and suggests that more affluent men are more apt to seek newer treatment modalities for prostate cancer. 27 
Limitations
The findings of this study are subject to the inherent biases of its retrospective nature. These data were derived from the NCDB registry, which comprehensively tabulates an estimated 70% of all new cancer diagnoses, 14, 15 thus limiting the scope of our study to roughly two-thirds of patients diagnosed as having prostate cancer from 2010 to 2015. Despite the thorough data collected by the NCDB, it does not collect information on ADT duration, compliance, and adverse effects. However, because the present study was not intended to report on survival or efficacy, this information would have added significant depth to the analyses but was not vital to our findings. In addition, because the NCDB does not comprehensively capture nuances in RT delivery, future studies are warranted to characterize trends in specific RT planning factors, such as image guidance, use of a rectal balloon, spacers or fiducials, treatment platform (CyberKnife vs linear accelerator), and whether all 5 treatment fractions are delivered on consecutive days. These adjunct technological advances designed to facilitate accurate and safe hypofractionated treatment require physician training and comfort and may also be associated with the frequency at which SBRT is recommended.
Conclusions
This study found that the use of SBRT as a definitive treatment modality in prostate cancer more than doubled from 2010 to 2015. Androgen deprivation therapy use increased with risk among patients overall, regardless of receiving SBRT. Patients who were treated at an academic center, lived in an urban environment, had higher incomes, were healthier, and were diagnosed as having lower-risk prostate cancer were more likely to receive SBRT. Further investigation is warranted to validate the potential disparities in SBRT implementation to identify and rectify the underlying causes. In addition, the continued use of SBRT will be contingent on ongoing studies reporting long-term outcomes in low-risk prostate cancer and the role of SBRT in higher-risk prostate cancer.
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